Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
18.64
-0.55 (-2.87%)
At close: Sep 11, 2026, 4:00 PM EDT
18.85
+0.21 (1.13%)
After-hours: Sep 11, 2026, 7:38 PM EDT

Legend Biotech Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Legend Biotech stock has a consensus rating of "Buy" and an average price target of $49.25. The average 1-year stock price forecast is 164.22% higher than the current stock price, while the lowest is $24 (+28.76%) and the highest is $78 (+318.45%).

Price Target: $49.25 (+164.22%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$24$49.25$49$78
Change+28.76%+164.22%+162.88%+318.45%

Analyst Ratings

The average analyst rating for Legend Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy987655
Buy555555
Hold222455
Sell000000
Strong Sell000000
Total161514151515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Barclays
Barclays
Buy
Maintains
$78$74
BuyMaintains$78$74+297.00%Sep 11, 2026
RBC Capital
RBC Capital
Buy
Maintains
$58
BuyMaintains$58+211.16%Sep 9, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$65
BuyReiterates$65+248.71%Sep 4, 2026
UBS
UBS
Hold
Reiterates
$28
HoldReiterates$28+50.21%Aug 13, 2026
Morgan Stanley
Morgan Stanley
Buy
Maintains
$49$48
BuyMaintains$49$48+157.51%Aug 12, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.43B
from 1.03B
Increased by 39.38%
Revenue Next Year
1.81B
from 1.43B
Increased by 26.31%
EPS This Year
-0.01
from -1.60
EPS Next Year
1.05
from -0.01
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
68.83M117.01M285.10M627.30M1.03B1.43B
Revenue Growth
-8.23%70.00%143.67%120.03%64.02%39.38%
Gross Profit
68.83M51.64M140.90M392.70M620.80M800.81M
Gross Margin
100.00%44.14%49.42%62.60%60.34%55.84%
Operating Income
-394.02M-458.05M-528.10M-305.10M-136.50M10.94M
Net Income
-403.58M-446.35M-518.30M-177.00M-296.80M-12.85M
EPS
-----1.60-0.01
Free Cash Flow
-122.84M-202.66M-496.78M-40.55M-133.99M44.00M
No. Analysts
-----11
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.5B
Avg1.4B
Low1.4B

Revenue Growth

Revenue Growth202620272028
High
43.2%
Avg
39.4%
Low
35.2%

EPS Forecast

EPS202620272028
High-0.01
Avg-0.01
Low-0.01

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-